false 0001527728 0001527728 2024-06-27 2024-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 27, 2024

 

RENOVARO INC.
(Exact name of registrant as specified in its charter)

 

Delaware   000-54478   45-2559340
(State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
of incorporation)   Identification No.)

 

2080 Century Park East, Suite 906

Los Angeles, CA 90067

 

(Address of principal executive offices)

+1(305) 918-1980

 

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share   RENB   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 27, 2024, Leni Boeren provided notice of her resignation as a member of the Board of Directors of Renovaro Inc. (the “Company”), with such resignation being effective June 27, 2024. Ms. Boeren’s decision is due to family health reasons requiring her time and attention and not a result of any disagreement on any matter relating to the Company’s management, policies, or practices. Ms. Boeren served as chair of the Company’s special litigation committee.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RENOVARO INC.
   
  By: /s/ Mark Dybul
  Name: Mark Dybul, M.D.
  Title: Chief Executive Officer

 

Date: July 3, 2024

 

3

 

 

v3.24.2
Cover
Jun. 27, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 27, 2024
Entity File Number 000-54478
Entity Registrant Name RENOVARO INC.
Entity Central Index Key 0001527728
Entity Tax Identification Number 45-2559340
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2080 Century Park East
Entity Address, Address Line Two Suite 906
Entity Address, City or Town Los Angeles
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90067
City Area Code (305)
Local Phone Number 918-1980
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol RENB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Enochian Biosciences (NASDAQ:ENOB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Enochian Biosciences.
Enochian Biosciences (NASDAQ:ENOB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Enochian Biosciences.